The Evolving Landscape of Disease Modification in Atopic Dermatitis - Current Evidence and Future Directions
Discover insights into disease-modifying approaches in atopic dermatitis (AD) management with these curated highlight clips from an exclusive webinar featuring Prof. Thomas Bieber, M.D., Ph.D., M.D.R.A., Prof. h.c., one of the world's foremost authorities in dermatology and atopic dermatitis research.
Originally presented on December 11, 2025, these bite-sized video segments capture the most impactful moments from Prof. Bieber's comprehensive presentation on the paradigm shift from symptomatic management to disease modification in atopic dermatitis care. Each clip delivers focused insights on how early intervention and targeted therapeutic approaches can fundamentally alter the disease trajectory and improve long-term outcomes for patients across all age groups.
AD: A highly complex immunological mechanism underlying a complex phenotype |
Concept of atopic march and it's impact on overall QOL |
The on-therapy complete disease control |
Treatment and guidelines |
How long to use the treatments? |
Efficacy and safety with dupilumab treatment |
Mechanisms of the skin inflammation and trained immunity |
Early intervention and off-drug remission |
Disease modification: what does this mean? |
LIBERTY PED-OLE: Off-therapy results in adolescent and children |
CCL17 (TARC) and IgE levels with biologics and JAK inhibitors |
Try to hit hard and early |
Speaker
|
Prof. Thomas Bieber, MD, PhD, MDRA
Department of Dermatology and Allergy, University Hospital, |
Bevestig uw status
Bevestig uw status
Sanofi biedt u exclusieve content over onze verschillende therapeutische gebieden op één portal
speciaal voor professionals in de gezondheidszorg, inclusief wetenschappelijk nieuws, een ljst met
evenementen en tools en diensten voor uw dagelijkse praktik.